BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 29971496)

  • 1. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
    Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
    J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
    Lyoo CH; Ryu YH; Lee MJ; Lee MS
    Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
    Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
    Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease.
    Spiegel J; Hellwig D; Samnick S; Jost W; Möllers MO; Fassbender K; Kirsch CM; Dillmann U
    J Neural Transm (Vienna); 2007 Mar; 114(3):331-5. PubMed ID: 16715205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
    Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
    Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease.
    Mito Y; Yabe I; Yaguchi H; Takei T; Terae S; Tajima Y
    Parkinsonism Relat Disord; 2018 May; 50():37-41. PubMed ID: 29449184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor dopaminergic response of impaired dexterity in Parkinson's disease: Bradykinesia or limb kinetic apraxia?
    Gebhardt A; Vanbellingen T; Baronti F; Kersten B; Bohlhalter S
    Mov Disord; 2008 Sep; 23(12):1701-6. PubMed ID: 18649388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson's disease.
    Lee YH; Cha J; Chung SJ; Yoo HS; Sohn YH; Ye BS; Lee PH
    Sci Rep; 2019 Jul; 9(1):10531. PubMed ID: 31324895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
    Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
    Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
    Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.
    Erro R; Pappatà S; Amboni M; Vicidomini C; Longo K; Santangelo G; Picillo M; Vitale C; Moccia M; Giordano F; Brunetti A; Pellecchia MT; Salvatore M; Barone P
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1034-8. PubMed ID: 22789824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
    Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
    Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.